Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic Study of Sorafenib in Egyptian HCC
NCT06030895Completed
- Sponsor
- Damanhour University
- Start
- Dec 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Damanhour University. Primary endpoints: ATG10 genotyping at 6 months, IL6 genotyping at 6 months and 1 more. Started Dec 2022; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06030895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030895.